Hein T W, Wang W, Zoghi B, Muthuchamy M, Kuo L
Department of Medical Physiology, Cardiovascular Reseach Institute, The Texas A&M University System Health Science Center, College Station, TX 77843-1114, USA.
J Mol Cell Cardiol. 2001 Feb;33(2):271-82. doi: 10.1006/jmcc.2000.1298.
Adenosine is a potent vasodilator of the coronary microvessels and is implicated in the regulation of coronary blood flow during metabolic stress. However, the receptor subtypes and the vasodilatory mechanism responsible for the dilation of coronary microvessels to adenosine remain unclear. In the present study, using an isolated-vessel preparation we demonstrated that porcine coronary arterioles (50-100 microm) dilated concentration-dependently to adenosine, CPA (adenosine A1 receptor agonist) and CGS21680 (adenosine A2A receptor agonist). These vasodilations were not altered by the A1 receptor antagonist CPX, but were abolished by the selective A2A receptor antagonist ZM241385, indicating that activation of A2A receptors mediates these vasodilatory responses. The protein kinase A inhibitor Rp-8-Br-cAMPS abolished coronary arteriolar dilations to adenylyl cyclase activator forskolin and cAMP analog 8-Br-cAMP, but failed to inhibit adenosine- and CGS21680-induced dilations. The calcium-activated potassium channel inhibitor iberiotoxin also did not affect vasodilations to adenosine and CGS21680. In contrast, the ATP-sensitive potassium (K(ATP)) channel inhibitor glibenclamide abolished vasodilations to adenosine and CGS21680 but did not affect vasodilations to forskolin and 8-Br-cAMP. In addition, the cAMP level in coronary microvessels was not increased by adenosine or CGS21680. The results from RT/PCR and in situ hybridization indicated that adenosine A2A receptor mRNA was encoded in coronary arterioles and the left anterior descending (LAD) artery but not in cardiomyocytes, whereas the A1 receptor transcript was detected in the LAD artery and cardiomyocytes but not in arterioles. Similarly, adenosine A1 and A2A proteins were expressed in the LAD artery, but only A2A receptors were expressed in coronary arterioles. Collectively, these functional data suggest that coronary arteriolar dilation to adenosine is primarily mediated by the opening of K(ATP) channels through activation of A2A receptors. This conclusion is corroborated by the molecular data showing that coronary arterioles only express adenosine A2A receptors. Furthermore, the dilation of coronary microvessels to adenosine A2A receptor activation appears to be independent of cAMP signaling.
腺苷是冠状动脉微血管的强效血管扩张剂,参与代谢应激期间冠状动脉血流的调节。然而,负责冠状动脉微血管对腺苷扩张反应的受体亚型和血管舒张机制仍不清楚。在本研究中,我们使用离体血管制备方法证明,猪冠状动脉小动脉(50 - 100微米)对腺苷、CPA(腺苷A1受体激动剂)和CGS21680(腺苷A2A受体激动剂)呈浓度依赖性扩张。这些血管舒张反应不受A1受体拮抗剂CPX的影响,但被选择性A2A受体拮抗剂ZM241385消除,表明A2A受体的激活介导了这些血管舒张反应。蛋白激酶A抑制剂Rp - 8 - Br - cAMPS消除了冠状动脉小动脉对腺苷酸环化酶激活剂福斯高林和cAMP类似物8 - Br - cAMP的舒张反应,但未能抑制腺苷和CGS21680诱导的舒张反应。钙激活钾通道抑制剂iberiotoxin也不影响对腺苷和CGS21680的血管舒张反应。相反,ATP敏感性钾(K(ATP))通道抑制剂格列本脲消除了对腺苷和CGS21680的血管舒张反应,但不影响对福斯高林和8 - Br - cAMP的血管舒张反应。此外,腺苷或CGS21680不会增加冠状动脉微血管中的cAMP水平。RT/PCR和原位杂交结果表明,腺苷A2A受体mRNA在冠状动脉小动脉和左前降支(LAD)动脉中编码,但在心肌细胞中不编码,而A1受体转录本在LAD动脉和心肌细胞中检测到,但在小动脉中未检测到。同样,腺苷A1和A2A蛋白在LAD动脉中表达,但只有A2A受体在冠状动脉小动脉中表达。总体而言,这些功能数据表明,冠状动脉小动脉对腺苷的舒张主要是通过激活A2A受体使K(ATP)通道开放介导的。这一结论得到了分子数据的证实,即冠状动脉小动脉仅表达腺苷A2A受体。此外,冠状动脉微血管对腺苷A2A受体激活的舒张似乎独立于cAMP信号传导。